Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17300185 | 1.00 | GABRR1 (0.41) | GABRR1CYP1A2FOLH1NAALAD2MAPT | |
| SCHEMBL19352706 | 1.00 | GABRR1 (0.41) | GABRR1CYP1A2FOLH1NAALAD2MAPT | |
| SCHEMBL23180523 | 0.81 | KDM4E (0.46) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL21566859 | 0.81 | ATM (0.36) | MAPTATMMCL1LMNA | |
| SCHEMBL16578166 | 0.80 | ALDH1A1 (0.36) | MAPTATMMCL1LMNA | |
| SCHEMBL14594076 | 0.80 | ALDH1A1 (0.36) | MAPTATMMCL1LMNA | |
| SCHEMBL25773392 | 0.80 | MMP9 (0.37) | MAPTATMMCL1LMNA | |
| SCHEMBL24697207 | 0.78 | ATM (0.37) | GABRR1MAPTATMMCL1LMNA | |
| SCHEMBL24760234 | 0.78 | FOLH1 (0.43) | GABRR1CYP1A2FOLH1NAALAD2LMNA | |
| SCHEMBL13697029 | 0.78 | GABRR1 (0.44) | GABRR1CYP1A2FOLH1NAALAD2ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024110905-A1 | ANTI-CEA ANTIBODY DRUG CONJUGATES AND METHODS OF USE | BEIGENE, LTD. (KY) | 2024-05-30 | — | — | WO | disclosed |
| WO-2023225336-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023215740-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | SEAGEN INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| EP-4227310-A1 | CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE THEREOF | Sichuan Baili Pharmaceutical Co. Ltd. (CN) | 2023-08-16 | — | — | EP | disclosed |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-20230190966-A1 | COMPOSITIONS USEFUL FOR TREATING GM1 GANGLIOSIDOSIS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2023-06-22 | — | — | US | disclosed |
| WO-2023098889-A1 | ANTI-HUMAN TROP2 ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND MEDICAL USE THEREOF | 成都百利多特生物药业有限责任公司 | 2023-06-08 | — | — | WO | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023082277-A1 | TOUGHENED POLYAMIDE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023083381-A1 | BISPECIFIC ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF | 成都百利多特生物药业有限责任公司 | 2023-05-19 | — | — | WO | disclosed |
| US-20080261849-A1 | Composition | RECKITT BENCKISER N.V. (NL) | 2008-10-23 | — | — | US | disclosed |
| WO-2008075084-A1 | DETERGENT COMPOSITION | RECKITT BENCKISER N.V. (NL) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146771-A1 | Maleamic acid polymer derivatives and their bioconjugates | NEKTAR THERAPEUTICS | 2008-06-19 | — | — | US | disclosed |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS | 2008-03-06 | — | — | US | disclosed |
| US-20070104757-A1 | LATENT REACTIVE BLOOD COMPATIBLE AGENTS | Surmodics Coatings, LLC | 2007-05-10 | — | — | US | disclosed |
| WO-2007052064-A1 | COMPOSITION | RECKITT BENCKISER N.V. (NL) | 2007-05-10 | — | — | WO | disclosed |
| US-20070084800-A1 | Use of amino acid and carbohydrate polymers in soil retention, water conservation, and water clarification | AQUERO COMPANY, LCC | 2007-04-19 | — | — | US | disclosed |
| US-20070085055-A1 | Amino acid and carbohydrate polymers for use in soil retention, water conservation, water clarification, and dust control | AQUERO COMPANY, LCC | 2007-04-19 | — | — | US | disclosed |
| US-20070082022-A1 | LATENT REACTIVE BLOOD COMPATIBLE AGENTS | Surmodics Coatings, LLC | 2007-04-12 | — | — | US | disclosed |
| US-20070039365-A1 | Slow-release fertilizer and method of making and using same | REGAL CHEMICAL COMPANY | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BUB1B, KIF5B, TK1 | GABRR1 4175/4885CYP1A2 3159/4885FOLH1 317/4885 |
| US-20230190966-A1 | COMPOSITIONS USEFUL FOR TREATING GM1 GANGLIOSIDOSIS | GALC, GBA1, GBA2 | GABRR1 1308/4885CYP1A2 4468/4885FOLH1 382/4885 |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | F8, F13A1, F13B | GABRR1 1890/4885CYP1A2 1486/4885FOLH1 151/4885 |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | GABRR1 2224/4885CYP1A2 4735/4885FOLH1 6/4885 |
| US-20070082022-A1 | LATENT REACTIVE BLOOD COMPATIBLE AGENTS | FGB, HLA-A, HLA-C | GABRR1 1615/4885CYP1A2 1735/4885FOLH1 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.